1026484-23-0

Basic information

• Product Name: 1-(4-morpholinylsulfonyl)-3-({4-[4-(trifluoromethoxy)phenoxy]phenyl}sulfanyl)acetone
• Synonyms: 1-(4-morpholinylsulfonyl)-3-({4-[4-(trifluoromethoxy)phenoxy]phenyl}sulfanyl)acetone
• CAS NO: 1026484-23-0
• Molecular Weight: 491.509
• Mol File: 1026484-23-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: 1-(4-morpholinylsulfonyl)-3-({4-[4-(trifluoromethoxy)phenoxy]phenyl}sulfanyl)acetone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-morpholinylsulfonyl)-3-({4-[4-(trifluoromethoxy)phenoxy]phenyl}sulfanyl)acetone(1026484-23-0)
• EPA Substance Registry System: 1-(4-morpholinylsulfonyl)-3-({4-[4-(trifluoromethoxy)phenoxy]phenyl}sulfanyl)acetone(1026484-23-0)

Safety Data

• Hazardous Substances Data: 1026484-23-0(Hazardous Substances Data)

Upstream product

• 361547-21-9 dithiocarbonic acid O-ethyl ester S-(4-(4-trifluoromethoxyphenoxy)phenyl) ester 
• 74030-44-7 1-nitro-4-(4-(trifluoromethoxy)phenoxy)benzene 
• 220616-47-7 4-(4'-trifluoromethoxyphenoxy)-benzenethiol 
• 350-46-9 4-Fluoronitrobenzene 
• 828-27-3 4-Trifluoromethoxyphenol 
• 1697-34-3 4-methanesulfonylmorpholine 
• 361547-22-0 methyl (4-(4-trifluoromethoxyphenoxy)phenylsulfanyl)acetate 

Relevant articles and documents

Phenoxyphenyl sulfone N-formylhydroxylamines (Retrohydroxamates) as potent, selective, orally bioavailable matrix metalloproteinase inhibitors

A novel series of sulfone N-formylhydroxylamines (retrohydroxamates) have been investigated as matrix metalloproteinases (MMP) inhibitors. The substitution of the ether linkage of ABT-770 (5) with a sulfone group 13a led to a substantial increase in activity against MMP-9 but was accompanied by a loss of selectivity for inhibition of MMP-2 and -9 over MMP-1 and diminished oral exposure. Replacement of the biphenyl P1′ substituent with a phenoxyphenyl group provided compounds that are highly selective for inhibition of MMP-2 and -9 over MMP-1. Optimization of the substituent adjacent to the retrohydroxamate center in this series led to the clinical candidate ABT-518 (6), a.highly potent, selective, orally bioavailable MMP inhibitor that has been shown to significantly inhibit tumor growth in animal cancer models.